Ascoli V, Carnovale-Scalzo C, Taccogna S, Nardi F
Dipartimento di Medicina Sperimentale e Patologia, Università La Sapienza, Roma, Italy.
Cytopathology. 1997 Oct;8(5):328-35. doi: 10.1111/j.1365-2303.1997.tb00557.x.
HBME-1 is an anti-mesothelial cell monoclonal antibody derived from human mesothelioma cells. We investigated 227 body cavity effusions to test its utility in differentiating mesothelioma from adenocarcinoma. HBME-1 outlined cell membranes in non-neoplastic mesothelial cells. Thick surface staining was observed on all mesotheliomas. HBME-1 reactivity was also detected in 24% of metastatic carcinomatous effusions. Most ovarian carcinomas (83%) reacted with this antibody, showing surface staining. Cytoplasmic HBME-1 immunoreactivity was observed in a small proportion of non-ovarian adenocarcinomas (14%). Despite its limited specificity, HBME-1 might be added to the battery of other markers of epithelial and/or mesothelial differentiation to be used in cases of suspected mesothelioma. Evaluation of suspicious cells should include careful study of the pattern of immunostaining.
HBME-1是一种源自人恶性间皮瘤细胞的抗间皮细胞单克隆抗体。我们研究了227例体腔积液,以测试其在鉴别间皮瘤和腺癌方面的效用。HBME-1勾勒出非肿瘤性间皮细胞的细胞膜。在所有间皮瘤中均观察到厚的表面染色。在24%的转移性癌性积液中也检测到HBME-1反应性。大多数卵巢癌(83%)与该抗体反应,表现为表面染色。在一小部分非卵巢腺癌(14%)中观察到细胞质HBME-1免疫反应性。尽管其特异性有限,但在疑似间皮瘤的病例中,HBME-1可添加到其他上皮和/或间皮分化标志物组合中。对可疑细胞的评估应包括仔细研究免疫染色模式。